Over the next decade, the diagnosed incidence of breast
cancer (CaB) in Mexico will increase at almost three times the average annual
growth rate in the major pharmaceutical markets (United States, France, Germany,
Italy, Spain, United Kingdom, and Japan). This growing incident population and
the launches of several novel high-value agents will be the key drivers of
market growth for CaB in Mexico through 2016. Mexico’s lack of legal
requirement for clinical trials in the local population, as well as the
progressive and well-informed physician community, offers significant
opportunity to multinational companies (MNCs) with emerging therapies in this
indication. In this report, we examine the trends within Mexico’s CaB therapy
market, which is characterized by the widespread use of molecular testing, a
near-universal healthcare system, and the anticipated uptake of several
Questions Answered in This Report:
Almost 60% of CaB cases in Mexico are diagnosed with
late-stage disease. How does Mexico’s stage distribution at diagnosis
compare that in the major markets? Will Mexico see changes in screening
practices that will affect CaB stage distribution in the next five years? How
does incidence of CaB translate into drug-treated CaB cases in Mexico?
The majority of the surveyed oncologists in Mexico report
following NCCN treatment guidelines for CaB. How similar is medical practice
for the treatment of CaB in Mexico to that in the major markets? Do oncologists
report significant constraints in access and reimbursement of targeted
therapies? What has been the impact of the FDA’s decision to revoke
bevacizumab’s CaB label on the drug’s uptake in Mexico?
By 2016, five new therapies are expected to enter Mexico’s
CaB market. How widely will these agents be used in Mexico and will they
offer much competition to current therapies? What are Mexican oncologists’
perceptions of the emerging therapies, and how do they see them positioned
against each other?
Primary research: 90 oncologists surveyed across Mexico.
Separate in-depth interviews with 8 oncologists from Mexico.
Epidemiology: Total incident cases as well as
progressed incidence cases of CaB in Mexico over a ten-year period (2011-2021) by
age and stage.
Current therapies and medical practice: Reporting use
of brands and generics for the CaB treatments available in Mexico.
Pricing and reimbursement: Prices of CaB therapies in
Mexico versus other major markets and analysis of the impact of government
reimbursement on treatment trends.
Market forecast features: Our analysis evaluates
rates of CaB progression and rates of drug treatment with CaB therapies across
all stages of the disease. We include a detailed forecast of current and
emerging therapies within the categories of selective estrogen receptor
modulators, aromatase inhibitors, selective estrogen receptor downregulators,
antimetabolites and other cytotoxics, anthracyclines, antitubulins,
HER2-targeting agents, angiogenesis inhibitors, and mTOR inhibitors from 2011
through 2016, using an epidemiology-based, bottom-up market model.